top of page
  • Completed

NCT02951819: Phase 2 - Evaluate Dara-CyBorD in Previously Untreated and RRMM - LYRA

Updated: Apr 14, 2022

A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma


Dara-CyBorD - Lyra Study


NCT02951819: Phase 2 - Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma - LYRA


Newly Diagnosed Multiple Myeloma

Relapsed Refractory Multiple Myeloma


The purpose of this study is to evaluate complete response plus (+) very good partial response (CR+VGPR) rate following 4 cycles of induction therapy of daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD), in previously untreated subjects, and in relapsed subjects with multiple myeloma, as defined by the International Myeloma Working Group (IMWG) criteria.


Sponsor:

Janssen Scientific Affairs, LLC


Multiple locations


Subjects will receive Daratumumab along with Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) as induction on a 28-day cycle length and Daratumab and Dexamethasone on Day 1 of each cycle for 12 cycles as maintenance therapy.

ClinicalTrials.gov Identifier: NCT02951819


Official Title: Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma

Click here to see details on ClinicalTrials.gov

 

Daratumumab : National Cancer Institute